Twist Bioscience
TWST
155.65
-11.32
-6.78%
Twist Bioscience
US · TWST
#1258 by market cap
Listed 2018
155.65
-11.32
-6.78%
Live - 5344 symbols - heartbeat 104s ago
· 2026-10-08 06:50
Pre-market
151.80
-2.47%
After-hours
155.50
-0.10%
Overnight
154.61
-0.67%
- Market cap
- 10.32B
- P/E (TTM)i
- -69.80
- P/Bi
- 23.15
- EPSi
- -1.30
- Div yieldi
- 0.00%
- 52W posi
- 67%
Reader sentiment
Are you bullish or bearish on TWST?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 34.12, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +20.32% YoY
Margins
- Gross margin
- 50.72%
- Operating margin
- -36.18%
- Net margin
- -20.63%
Key ratios & quality
- Altman Z-Scorei
- 34.12
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25.43M | 54.39M | 90.10M | 132.33M | 203.57M | 245.11M | 312.97M | 376.57M |
| Gross profit | -6.76M | 6.96M | 28.69M | 51.71M | 84.24M | 89.73M | 133.35M | 191.00M |
| Selling & admin expenses | 43.45M | 80.13M | 103.27M | 135.90M | 212.95M | 189.74M | 218.40M | 246.98M |
| Research & development | 20.35M | 35.68M | 43.01M | 69.07M | 120.31M | 106.89M | 90.85M | 80.29M |
| Operating profit | -70.56M | -108.85M | -117.58M | -153.26M | -249.02M | -206.90M | -175.90M | -136.26M |
| Pretax profit | -70.99M | -107.38M | -139.55M | -154.03M | -228.27M | -203.47M | -208.17M | -76.95M |
| Tax | 242.00K | 292.00K | 382.00K | -1.93M | -10.41M | 1.15M | 560.00K | 719.00K |
| Net profit | -71.24M | -107.67M | -139.93M | -152.10M | -217.86M | -204.62M | -208.73M | -77.67M |
| Basic EPS | -3 | -4 | -4 | -3 | -4 | -4 | -4 | -1 |
| Diluted EPS | -2.68 | -3.92 | -3.57 | -3.15 | -4.04 | -3.60 | -3.60 | -1.30 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 92.79M | 96.06M | 99.01M | 103.70M | 110.72M | 118.38M |
| Gross profit | 46.03M | 51.30M | 50.84M | 53.97M | 57.12M | 62.45M |
| Selling & admin expenses | 63.67M | 63.37M | 63.76M | 69.94M | 76.09M | 80.71M |
| Research & development | 23.92M | 18.05M | 17.01M | 17.13M | 19.70M | 18.03M |
| Operating profit | -41.56M | -30.12M | -29.93M | -33.10M | -38.66M | -36.28M |
| Pretax profit | -39.15M | 20.58M | -26.88M | -30.25M | -43.98M | -34.74M |
| Tax | 175.00K | 191.00K | 257.00K | 253.00K | 43.00K | 311.00K |
| Net profit | -39.33M | 20.39M | -27.14M | -30.51M | -44.02M | -35.05M |
| Basic EPS | -1 | 0 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.66 | 0.33 | -0.45 | -0.50 | -0.71 | -0.56 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 95.67M | 160.14M | 334.87M | 546.50M | 596.48M | 424.26M | 346.78M | 332.97M |
| Cash & ST investments | 80.76M | 138.11M | 290.00M | 477.86M | 504.97M | 336.41M | 276.40M | 232.43M |
| Inventory | 6.03M | 7.33M | 12.29M | 31.80M | 39.31M | 32.06M | 24.08M | 28.31M |
| Total assets | 115.79M | 186.99M | 398.88M | 702.10M | 961.38M | 776.40M | 614.32M | 641.86M |
| Total current liabilities | 18.54M | 30.35M | 36.03M | 63.05M | 90.66M | 73.32M | 71.01M | 91.41M |
| Short-term debt | 2.50M | 3.33M | 9.74M | 9.77M | 13.64M | 14.90M | 14.81M | 13.82M |
| Long-term debt | 7.22M | 4.40M | 1.40M | -- | -- | -- | -- | -- |
| Total liabilities | 317,213,000.00 | 34,912,000.00 | 62,620,000.00 | 121,276,000.00 | 171,993,000.00 | 152,971,000.00 | 141,634,000.00 | 168,903,000.00 |
| Total equity | -201.42M | 152.08M | 336.26M | 580.82M | 789.39M | 623.43M | 472.69M | 472.96M |
| Retained earnings | -210.86M | -318.52M | -458.46M | -610.55M | -828.42M | -1.03B | -1.24B | -1.32B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 338.44M | 339.78M | 332.97M | 303.88M | 323.44M | 321.30M |
| Cash & ST investments | 257.15M | 250.80M | 232.43M | 197.95M | 171.67M | 166.84M |
| Inventory | 20.86M | 25.94M | 28.31M | 32.92M | 33.52M | 35.16M |
| Total assets | 595.62M | 643.61M | 641.86M | 638.09M | 676.21M | 672.44M |
| Total current liabilities | 74.98M | 87.07M | 91.41M | 80.44M | 119.98M | 120.26M |
| Short-term debt | 15.22M | 15.50M | 13.82M | 12.24M | 10.44M | 8.63M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 155,507,000.00 | 165,407,000.00 | 168,903,000.00 | 181,990,000.00 | 221,120,000.00 | 226,698,000.00 |
| Total equity | 440.11M | 478.20M | 472.96M | 456.10M | 455.09M | 445.74M |
| Retained earnings | -1.31B | -1.29B | -1.32B | -1.35B | -1.39B | -1.43B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -66.16M | -87.94M | -142.26M | -112.24M | -124.39M | -142.47M | -64.09M | -47.63M |
| Depreciation & amortization | 5.73M | 6.11M | 6.68M | 9.75M | 16.51M | 29.31M | 31.43M | 24.85M |
| Free cash flow | -69.85M | -102.69M | -152.12M | -139.31M | -226.24M | -170.25M | -69.17M | -75.63M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 156.21M | 293.14M | 313.01M | 262.07M | -4.41M | -3.98M | -16.00K |
| Ending cash balance | 81.54M | 47.40M | 94.25M | 467.36M | 380.26M | 289.28M | 229.13M | 185.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -12.99M | -1.40M | -11.81M | -24.81M | -17.56M | 1.12M |
| Depreciation & amortization | 6.40M | 6.07M | 6.00M | 6.19M | 6.41M | 6.78M |
| Free cash flow | -17.13M | -10.57M | -24.24M | -34.79M | -25.55M | -8.65M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -5.00K | -3.00K | -2.00K | -2.00K | -8.00K | -6.00K |
| Ending cash balance | 212.95M | 203.91M | 185.43M | 150.99M | 124.85M | 119.57M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -57.31 | -33.17 | -31.80 | -28.97 | -38.08 | -16.43 |
| ROA %i | -70.72 | -71.12 | -47.77 | -27.63 | -26.19 | -23.55 | -30.02 | -12.37 |
| ROIC %i | -- | -- | -52.80 | -29.95 | -28.89 | -26.88 | -35.14 | -15.57 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -37.87 | -29.69 |
| EBIT margin %i | -274.04 | -195.06 | -154.01 | -116.12 | -112.10 | -83.01 | -66.50 | -36.18 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.16 | 5.28 | 9.29 | 8.67 | 6.58 | 5.79 | 4.88 | 3.64 |
| Quick ratioi | 4.65 | 4.95 | 8.78 | 8.03 | 6.01 | 5.19 | 4.38 | 3.17 |
| Debt / assetsi | 8.39 | 4.14 | 9.02 | 8.96 | 9.87 | 12.12 | 13.84 | 11.77 |
| LT debt / equityi | -- | 2.89 | 7.80 | 9.15 | 10.30 | 12.70 | 14.86 | 13.06 |
| Interest coveragei | -53.07 | -81.98 | -176.32 | -418.69 | -2,852.43 | -40,692.20 | -7,177.14 | -- |
| Revenue CAGR (3Y) %i | -- | 188.32 | 103.02 | 73.30 | 55.27 | 39.60 | 33.23 | 22.76 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -38.22 | -17.58 | -16.43 | -16.79 | -18.16 | -29.59 |
| ROA %i | -29.44 | -13.29 | -12.37 | -12.29 | -12.78 | -20.78 |
| ROIC %i | -34.35 | -16.64 | -15.57 | -15.42 | -16.20 | -25.83 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -54.82 | -48.20 | -36.18 | -34.41 | -32.14 | -31.91 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.51 | 3.90 | 3.64 | 3.78 | 2.70 | 2.67 |
| Quick ratioi | 4.10 | 3.45 | 3.17 | 3.08 | 2.16 | 2.12 |
| Debt / assetsi | 13.48 | 12.14 | 11.77 | 15.37 | 14.17 | 13.92 |
| LT debt / equityi | 14.79 | 13.10 | 13.06 | 18.81 | 18.76 | 19.06 |
| Interest coveragei | -977.37 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Next-Generation Sequencing (NGS) applications is the largest reported line at 52.21% of revenue, across 2 reported segments.
- DNA synthesis and protein solutions follows at 47.79%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Next-Generation Sequencing (NGS) applications52.21%
DNA synthesis and protein solutions47.79%
Quote time 2026-10-08 06:50:15 · For reference only, not investment advice and not tailored to your situation.